Markets:

Overview

News

Currencies

International

Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

9.315 +0.245 (+2.70%)

Streaming Delayed Price Updated: 11:01 AM EDT, Aug 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why BioCryst Pharmaceuticals Stock Is Sinking Today ↗

February 21, 2023

Investors didn't like the drugmaker's Q4 update.

Via The Motley Fool

BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript ↗

February 21, 2023

BCRX earnings call for the period ending December 31, 2022.

Via The Motley Fool

Why BioCryst Pharmaceuticals Stock Is Sliding Today ↗

February 21, 2023

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Tuesday after the company reported worse-than-expected earnings results<

Via Benzinga

Biocryst Pharmaceuticals's Earnings Outlook ↗

February 20, 2023

Via Benzinga

BioCryst Pharmaceuticals Stock Is Tumbling: What's Going On? ↗

January 09, 2023

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday after the company announced preliminary fourth-quarter and full

Via Benzinga

TSLA Stock Price Prediction: What to Know as Analysts Slash Tesla Price Targets ↗

December 15, 2022

Tesla (TSLA) stock is in the news as price predictions continue to be a hot topic among traders after Elon Musk's Twitter purchase.

Via InvestorPlace

BioCryst Shelves Development Of Rare Blood Disorder Candidate ↗

December 15, 2022

Via Benzinga

Expert Ratings for BioCryst Pharmaceuticals ↗

November 02, 2022

Analysts have provided the following ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) within the last quarter:

Via Benzinga

BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript ↗

November 01, 2022

BCRX earnings call for the period ending September 30, 2022.

Via The Motley Fool

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.

Via Benzinga

Why Is Getaround (GETR) Stock Up 6% Today? ↗

December 15, 2022

Getaround (GETR) stock is on the move Thursday with heavy trading despite a lack of recent news concerning the car-sharing service.

Via InvestorPlace

BCRX Stock Sinks as BioCryst Discontinues Drug Development ↗

December 15, 2022

BioCryst Pharmaceuticals (BCRX) stock is falling on Thursday after revealing it's no longer developing BCX9930 for competitive reasons.

Via InvestorPlace

Novavax, Tesla, Western Digital And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

December 15, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday ↗

December 05, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84 ↗

November 11, 2022

The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.

Via Investor's Business Daily

4 Analysts Have This to Say About BioCryst Pharmaceuticals ↗

November 02, 2022

Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday ↗

November 02, 2022

Gainers

Via Benzinga

Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session ↗

November 01, 2022

Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads.

Via Benzinga

Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday ↗

November 01, 2022

U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

What's Going On With BioCryst Pharmaceuticals Stock Today? ↗

November 01, 2022

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Tuesday after the company reported third-quarter financial results.

Via Benzinga

BioCryst Pharmaceuticals: Q3 Earnings Insights ↗

November 01, 2022

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

BioCryst Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 10, 2022

On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.

Via Investor's Business Daily

Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap ↗

October 04, 2022

The company scrapped its hereditary angioedema drug due to safety issues.

Via Investor's Business Daily

3 Biotech Stocks to Buy Now for Extraordinary Gains ↗

September 20, 2022

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

Via InvestorPlace

BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate ↗

August 31, 2022

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BioCryst’s (NASDAQ: BCRX) lead asset BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).

Via Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary ↗

August 26, 2022

Via Benzinga

BioCryst Exhibits Positive Data From Early-Stage Rare Kidney Disease Study ↗

August 26, 2022

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that its lead asset BCX9930 has demonstrated >99 percent suppression of the alternative pathway (AP), and that >98 percent suppression was maintained...

Via Benzinga

US Government To Purchase Additional Influenza Treatment From BioCryst For Pandemic Preparedness ↗

August 25, 2022

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.